Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
IQVIA Holdings Inc. — The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. The filing states that on January 12, 2026 Vanguard completed an internal realignment and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
IQVIA Holdings Inc. is asking stockholders to vote at its 2026 annual meeting on five items, including electing directors, an advisory say‑on‑pay vote, ratifying PricewaterhouseCoopers as auditor, approving a new 2026 Incentive and Stock Award Plan, and a stockholder proposal opposed by the Board.
The company highlights 2025 revenue of $16.3 billion, Adjusted EBITDA of $3.8 billion, and Free Cash Flow of $2.1 billion, along with $1.8 billion in strategic acquisitions and $1.2 billion returned via repurchases of about 7.4 million shares.
IQVIA emphasizes AI leadership, record clinical development backlog of $32.7 billion, strong governance features such as a fully independent Board (other than the CEO), majority voting for directors, proxy access, special meeting rights, robust clawback policies, and an executive pay program heavily weighted to performance-based equity.
Haas Bernd reported disposition transactions in a Form 4 filing for IQV. The filing lists transactions totaling 20 shares at a weighted average price of $166.94 per share. Following the reported transactions, holdings were 24,394 shares.
IQVIA Holdings executive Michael J. Fedock reported a tax-related share disposition. On 02/13/2026, he transferred 123 shares of IQVIA common stock at $166.94 per share to cover tax obligations, as indicated by transaction code “F.” After this tax-withholding disposition, he directly owned 9,472 IQVIA shares.
IQVIA Holdings Inc. files its annual report describing a global healthcare data, technology and clinical research business with approximately 93,000 employees in over 100 countries. The company provides clinical trial services, real‑world evidence, analytics, and technology-enabled commercial solutions to life sciences and broader healthcare clients.
IQVIA highlights a large addressable market of about $335 billion across outsourced R&D, real‑world evidence and connected health, and technology‑enabled commercial operations. It reports extensive proprietary healthcare data, including more than 1.2 billion non‑identified patient records and roughly 68 petabytes of proprietary data from about 150,000 suppliers.
The filing details competitive dynamics, key growth strategies, extensive risk factors, data privacy and regulatory obligations, and its commitment to responsible, “Healthcare‑grade” AI and sustainability. As of June 30, 2025, non‑affiliate equity had an approximate market value of $26.5 billion, with about 169.7 million common shares outstanding as of February 6, 2026.
IQVIA Holdings Inc. reported that executive W. Richard Staub, President of Research & Development Solutions, received a grant of stock appreciation rights covering 26,088 shares of common stock on February 9, 2026. These rights have a $192.67 exercise price and vest in three equal annual installments beginning February 9, 2027.
IQVIA Holdings Inc. reported that executive officer Eric Sherbet, Executive Vice President and General Counsel, was granted a stock appreciation right on its common stock. The award covers 12,112 shares at a conversion or exercise price of $192.67 per share and was granted on February 9, 2026.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027 and expires on February 9, 2036. Following this grant, 12,112 derivative securities tied to IQVIA common stock are beneficially owned directly by the reporting person.
IQVIA Holdings Inc. reported that officer Bhavik Patel, President, MedTech and Consumer Health, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 derivative securities tied to 11,180 shares of common stock at a conversion or exercise price of $192.67.
These stock appreciation rights were acquired as a grant or award and are held directly. The award vests in three annual installments beginning on February 9, 2027, meaning the rights become exercisable over a three-year period starting on that date.
IQVIA Holdings Inc. executive Bernd Haas, EVP, AI and Technology Solutions, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 stock appreciation rights with a conversion or exercise price of $192.67 per right.
These stock appreciation rights vest in three annual installments beginning on February 9, 2027, and are held as a direct ownership position. After this grant, Haas beneficially owned 11,180 derivative securities tied to IQVIA common stock.